Viz.ai is an AI-powered care coordination platform for healthcare delivery. It uses FDA-cleared algorithms to help detect disease faster, streamline workflows, and improve treatment decisions across hospitals.
Access to pre-IPO shares is available to accredited investors through UpMarket.
Latest Price
$1.2B
Series D, Dec 2021, Perplexity
UpMarket Estimate
$1.1B
Based on UpMarket valuation model
Previous Price
$500M
Series C May 2020
How to Invest in Viz.ai Through UpMarket
Viz.ai shares are not on public exchanges. UpMarket provides accredited investors access through secondary market transactions.
Step 01
Verify accredited investor status
Confirm eligibility under SEC Rule 501 of Regulation D. Income or net worth threshold applies.
Step 02
Create an UpMarket account
Complete KYC/AML onboarding. Typically 1–2 business days. Licensed rep assigned on signup.
Step 03
Review available Viz.ai offerings
Full offering memoranda and risk disclosures provided before any commitment is required.
Step 04
Complete subscription documents
Review and sign subscription agreement. All documents handled digitally through the platform.
Step 05
Fund your investment
Wire transfer or ACH. $50K minimum. Funds held in custodial account until close.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
$1.3B+
UpMarket has brokered over $1.3 billion in alternative investments*
*Includes principal invested and appreciation of investments originated via the UpMarket platform based on historical trade volume and valuation estimates through March 31, 2026. Of the total, approximately $301 million is managed by UpMarket Management, with the remaining originated investments managed by affiliates. Past performance is not predictive of future results.
Valuation Growth Over Time
Post-money valuation by round
Previous roundsMost recent
Date
Round
PPS (split-adj.)
Valuation
Dec 2021
Series D
$1.2B
May 2020
Series C
$500M
Feb 2019
Series B
$250M
Jul 2018
Series A
$100M
Why Investors Are Watching Viz.ai
Growth Signal
Viz.ai said hospitals using its platform topped 1,000 in 2022
Viz.ai said its Series D was announced when the number of hospitals using the Viz Platform surpassed 1,000 and patients served reached millions. The round raised $100 million at a $1.2 billion valuation, led by Tiger Global and Insight Partners.
Competitive Moat
Viz.ai expanded to 60,000 providers across 1,700 hospitals
Viz.ai said its hospital footprint expanded to 1,700 hospitals and its user base grew more than 30% to reach 60,000 healthcare providers. It also announced new partnerships with three global pharmaceutical companies, extending distribution beyond hospitals.
Market Opportunity
Viz.ai targets faster diagnosis and care coordination in healthcare
Viz.ai says its AI platform analyzes medical imaging to accelerate diagnosis and reduce systemic delays that block life-saving treatments. The company’s mission is to improve access to care by transforming clinical workflow and patient care.
Interested in Viz.ai stock? Fill out the form above or sign up directly. Subject to availability. Accredited investors only.
UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
Strategy, fees & legal reviewed in full
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers — legal counsel, auditor, administrator, and custodian.
Disciplined managers only
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Built around your objectives
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
No. As of March 2026, Viz.ai is a private company and does not trade on any public stock exchange. Accredited investors can access Viz.ai shares through UpMarket, a FINRA-registered broker-dealer that specializes in pre-IPO investments.
Viz.ai does not have a public stock price because it is privately held. The most recent known share price comes from its last funding round. Pre-IPO share prices on the secondary market may differ from the last round price depending on supply, demand, and market conditions.
Yes. Accredited investors can indicate interest in Viz.ai shares through UpMarket by filling out the form on this page or creating an account at upmarket.co. All pre-IPO offerings are subject to availability and require a $50,000 minimum investment. UpMarket is a FINRA-registered broker-dealer and has brokered more than $500M in alternative investments since 2019.
Pre-IPO investments carry significant risks. Viz.ai shares are illiquid, meaning there is no public market to sell them quickly. There is no guaranteed exit timeline or return. The investment is speculative in nature, and investors should be prepared for the possibility of total loss. Valuations of private companies can fluctuate substantially between funding rounds. Investors should consult their financial advisor and review all offering documents before investing.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
There are two primary exit paths for pre-IPO holdings: selling your shares on the secondary market to another buyer, or holding until the company completes an IPO or is acquired. Both paths are subject to transfer restrictions, company approval (right of first refusal), and market conditions. The timing of any exit is unpredictable, and investors should plan for a multi-year holding period.
The minimum investment for most pre-IPO offerings on UpMarket is $50,000. This amount may vary depending on the specific offering and share availability. There are no fees to create an UpMarket account or browse available investments. Investors only pay transaction-related fees when they complete an investment.
UpMarket's valuation estimate of is derived from a proprietary model that incorporates multiple data sources: funding round data (Caplight), revenue estimates (Sacra), secondary market pricing, and public company comparables. The model applies a private company discount to the public comp multiple to account for illiquidity and information asymmetry. This estimate is not investment advice and may differ substantially from the price at which shares actually trade.
Viz.ai’s FDA-cleared AI care coordination platform helps hospitals detect disease faster and streamline treatment workflows, with adoption topping 1,000 hospitals in 2022; it was valued at $1.1B — accredited investors can access Viz.ai stock through UpMarket.